They’ll need to because they need a much larger sample size. This isn’t results of the current study in combo with Keytruda. This is the prior study and this is for a subgroup with in a larger study of all HER2 patients. That’s why they are focusing on that subgroup- triple negative. 20 yr follow up is great and shows the long lasting effect of linkage of a target to Ii-Key.